Versant Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Versant Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41	Closed	-$1.37K	–	2842
2026 Q1	$1.37K	Sell	41 -76	-65%	-$2.98K	﹤0.01%	2617
2025 Q4	$5.42K	Sell	117 -45	-28%	-$2.47K	﹤0.01%	2231
2025 Q3	$11K	Hold	162	–	–	﹤0.01%	1899
2025 Q2	$13.6K	Hold	162	–	–	﹤0.01%	1748
2025 Q1	$11.6K	Buy	162 +79	+95%	+$3.85K	﹤0.01%	1649
2024 Q4	$3.73K	Buy	+83	New	+$4.3K	﹤0.01%	1897

Versant Capital Management's SLNO Position: Q2 2026 in Review

Versant Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 41 shares — an estimated $1.37K sold.

Versant Capital Management first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $13.6K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Versant Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Versant Capital Management sold 41 Soleno Therapeutics shares in Q2 2026, an estimated $1.37K.
Versant Capital Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
Versant Capital Management's Soleno Therapeutics position peaked at $13.6K in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.